A randomized phase II study of axitinib in combination with pemetrexed/cisplatin (pem/cis) as first-line therapy for nonsquamous non-small cell lung cancer (NSCLC)

被引：0
|
作者：
Belani, Chandra Prakash
Yamamoto, Nobuyuki
Bondarenko, Igor
Orlov, Sergey V.
Tang, Jie
Niethammer, Andreas G.
Ingrosso, Antonella
Kim, Sinil
Scagliotti, Giorgio
机构：
[1] Penn State Hershey Canc Inst, Hershey, PA USA
[2] Shizuoka Canc Ctr, Nagaizumi, Shizuoka, Japan
[3] Dnipropetrovsk State Med Acad, Dnepropetrovsk, Ukraine
[4] St Petersburg Pavlov State Med Univ, St Petersburg, Russia
[5] Pfizer Inc, New York, NY USA
[6] Pfizer Oncol, San Diego, CA USA
[7] Pfizer Italia Srl, Milan, Italy
[8] Univ Torino, Orbassano, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7551
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A RANDOMIZED PHASE II STUDY OF AXITINIB PLUS PEMETREXED/CISPLATIN (PEM/CIS) FOR NON-SMALL-CELL LUNG CANCER (NSCLC)
    Ono, A.
    Yamamoto, N.
    Takahashi, T.
    Murakami, H.
    Naito, T.
    Kaira, K.
    Umeyama, Y.
    Belani, C. P.
    [J]. ANNALS OF ONCOLOGY, 2012, 23 : 86 - 86
  • [2] A phase II trial of first-line bevacizumab in combination with pemetrexed and carboplatin in advanced nonsquamous non-small cell lung cancer (NSCLC)
    Skaff, Z. G.
    Hageboutros, A.
    Krieger, K.
    Coakley, S.
    Somer, R.
    Stevenson, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [3] THE BUDGETARY IMPACT OF PEMETREXED PLUS CISPLATIN AS FIRST-LINE THERAPY FOR ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Wielage, R. C.
    Muehlenbein, C. E.
    Liepa, A. M.
    Babineaux, S. M.
    Klein, R. W.
    Schwartzberg, L. S.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A39 - A39
  • [4] Randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line chemotherapy in advanced non-small cell lung cancer.
    Nagel, S.
    Groeschel, A.
    Sebastian, M.
    Andreas, S.
    Mueller, T.
    Schneller, F.
    Guetz, S.
    Leschinger, M. I.
    Buettner, H.
    Reck, M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Phase II study of pemetrexed (Pem) and cisplatin (Cis) plus cetuximab (Cet) followed by Pem and Cet maintenance therapy in patients (Pts) with advanced nonsquamous non-small cell lung cancer (NSCLC).
    Schmid-Bindert, Gerald
    Gebbia, Vittorio
    Mayer, Frank
    Arriola, Edurne
    Marquez-Medina, Diego
    Syrigos, Konstantinos N.
    Biesma, Bonne
    Leschinger, Monika Iris
    Grul, Carla M. Visseren
    Frimodt-Moller, Bente
    Ripoche, Veronique
    Myrand, Scott
    Tuan Nguyen
    Zimmermann, Annamaria
    Schuette, Wolfgang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] PHARMACOKINETIC (PK) ANALYSIS OF COADMINISTRATION OF AXITINIB AND PEMETREXED/CISPLATIN (PEM/CIS) IN PATIENTS WITH NON-SMALL CELL LUNG CANCER (NSCLC).
    Tortorici, M. A.
    Iglesias, L.
    Kozloff, M. F.
    Pithavala, Y. K.
    Ingrosso, A.
    Belani, C. P.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S33 - S33
  • [7] First-line cisplatin plus pemetrexed therapy for selected patients with advanced nonsquamous non-small cell lung cancer.
    Nakashima, Kazuhisa
    Murakami, Haruyasu
    Imai, Hisao
    Ono, Akira
    Taira, Tetsuhiko
    Kenmotsu, Hirotsugu
    Naito, Tateaki
    Endo, Masahiro
    Takahashi, Toshiaki
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Wielage, Ron
    Schwartzberg, Lee
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (11) : 1404 - 1414
  • [9] Phase II study of bevacizumab, cisplatin, and pemetrexed as first-line chemotherapy for advanced nonsquamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-type.
    Murakami, Shuji
    Saito, Haruhiro
    Karino, Fumi
    Kondo, Tetsuro
    Oshita, Fumihiro
    Yamada, Kouzo
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [10] A Randomized Phase II Study of Pemetrexed in Combination With Cisplatin or Carboplatin as First-Line Therapy for Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
    Schuette, Wolfgang H. W.
    Groeschel, Andreas
    Sebastian, Martin
    Andreas, Stefan
    Mueller, Thomas
    Schneller, Folker
    Guetz, Sylvia
    Eschbach, Corinna
    Bohnet, Sabine
    Leschinger, Monika I.
    Reck, Martin
    [J]. CLINICAL LUNG CANCER, 2013, 14 (03) : 215 - 223
12345